Jay Feingold - 07 Oct 2021 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role: Chief Medical Officer
Signature: /s/ Pamela Connealy, Attorney-in-Fact for Jay Feingold
Issuer symbol: PYXS
Transactions as of: 07 Oct 2021
Net transactions value: $0
Form type: 4
Filing time: 12 Oct 2021, 19:47:46 UTC
Next filing: 04 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PYXS	Common Stock	Award	$0	+43,750		$0.000000	43,750	07 Oct 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PYXS	Stock Option (Right to buy)	Award	$0	+436,929		$0.000000	436,929	07 Oct 2021	Common Stock	436,929	$16.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of restricted stock that vest 25% of the first anniversary of September 13, 2021, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
F2	These stock options vest 25% on the first anniversary of September 13, 2021, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.